Telmisartan’s hidden longevity angle – what the latest paper says

Posted by hank_m in Research & News - 1 points, 0 comments.

’s 2024 work on telmisartan’s dual action as an ARB and partial PPAR‑gamma agonist, and i’m wondering if this is a legit longevity boost or just hype. The authors point out that the same drug we use for high blood pressure also improves insulin sensitivity and may even promote mitochondrial biogenesis, citing data from a small cohort of 45 seniors who had their blood work done after 12 weeks of 20‑mg daily dosing. I’m skeptical because the study size is tiny and the analysis is mostly cross‑sectional, but i’ve been on 40 mg for a year to keep my blood pressure in check and i’ve noticed better energy levels and a smoother recovery after training sessions.

The paper also warns about the dizziness and hypotension that can come with higher doses, which is a big deal for people who already lean low on blood pressure. Would anyone else be willing to try a trial dose the same way i did and log the metabolic markers? Any data on how it might affect longevity markers like IGF‑1 or inflammation would be great to hear.

Community discussion - research and educational context only. Not medical advice.